University of Arkansas for Medical Sciences Logo University of Arkansas for Medical Sciences
Translational Research Institute

TRI Study of the Month

The research team includes (front, l-r), TRI Research Coordinator Shellah Rogers, B.S.N., RN, Brooke Yancey-Ward, Psy.D., Principal Investigator Clare Nesmith, M.D., and TRI Research Coordinator Vallon Williams, DNP; (back, l-r) lead Research Coordinator Allyson Cheathem, B.S.N., RN, Co-Investigator Tara Venable, M.D., and TRI Research Coordinator Diana Gregory, RN
The research team includes (front, l-r), TRI Research Coordinator Shellah Rogers, B.S.N., RN, Brooke Yancey-Ward, Psy.D., Principal Investigator Clare Nesmith, M.D., and TRI Research Coordinator Vallon Williams, DNP; (back, l-r) lead Research Coordinator Allyson Cheathem, B.S.N., RN, Co-Investigator Tara Venable, M.D., and TRI Research Coordinator Diana Gregory, RN

UAMS Principal Investigator: Clare Nesmith, M.D., associate professor, College of Medicine Department of Pediatrics

Summary: A multi-site blinded trial comparing a rapid-wean intervention to a slow-wean intervention for newborns with neonatal opioid withdrawal syndrome (NOWS). Treatment is with either morphine or methadone. The rapid-wean cohort receives 15% reductions in either morphine or methadone, and the slow-wean cohort receives 10% reductions.

Significance: If the fast weaning proves to be safe and effective, it would reduce an infant’s time in the neonatal intensive care unit by
several days. TRI Services: Medicare coverage analysis, study budget development, administration of Clinical Trial Management System, clinical
research coordinator support, and post-award financial management

Sponsor: Advancing Clinical Trials in Neonatal Opioid Withdrawal (ACT NOW) Program with Eunice Kennedy Shriver National Institute of Child Health
and Human Development (NICHD).